Market cap
₹5 Cr
Revenue (TTM)
₹0 Cr
P/E Ratio
5.6
P/B Ratio
-0.1
Div. Yield
0 %
| Hiran Orgochem | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
5 | 31,863 | 30,485 | 28,611 | 27,284 |
Revenue (₹ Cr) |
-- | 3,564 | 1,936 | 9,205 | 1,462 |
Net Profit (₹ Cr) |
0.85 | 414.00 | 288.22 | -371.81 | 387.35 |
Net Margin (%) |
-- | 11.23 | 14.79 | -3.93 | 26.01 |
RoE (%) |
-- | 8.38 | 29.77 | -3.85 | 25.18 |
Price to Earnings |
5.56 | 77.90 | 105.77 | -- | 70.64 |
Price-To-Book |
-0.14 | 6.33 | 22.71 | 3.57 | 15.78 |
Income Statement (₹ Cr)
| Hiran Orgochem | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.42 | 4,481.54 | 39.21 | -- | 111.75 |
|
Total Income
|
1.30 | 4,548.09 | 39.54 | -- | 111.77 |
|
Total Expenditure
|
29.00 | 3,772.14 | 28.05 | -- | 103.45 |
|
EBITDA
|
-28.58 | 709.40 | 11.16 | -- | 8.29 |
|
Depreciation
|
0.05 | 145.40 | 5.18 | -- | 0.72 |
|
EBIT
|
-28.63 | 564.00 | 5.98 | -- | 7.58 |
|
Interest
|
0.01 | 55.21 | 2.37 | -- | 1.59 |
|
Other Income
|
0.88 | 66.55 | 0.33 | -- | 0.02 |
|
Exceptional Items
|
-- | 61.52 | -- | -- | -- |
|
Profit before Tax
|
-27.76 | 575.34 | 3.94 | -- | 6.01 |
|
Provision for Tax
|
-- | 162.65 | 1.27 | -- | 1.91 |
|
Profit after Tax
|
-27.76 | 412.69 | 2.67 | -- | 4.10 |
Liabilities (₹ Cr)
| Hiran Orgochem | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-62.36 | 3,715.35 | 47.49 | -- | 14.83 |
|
Minority Interest
|
-- | 143.95 | -- | -- | -- |
|
Non-Current Liabilities
|
0.69 | 1,872.46 | 11.98 | -- | 6.27 |
|
Current Liabilities
|
87.17 | 1,772.97 | 24.42 | -- | 37.80 |
|
Total Liabilities
|
25.49 | 7,504.73 | 83.90 | -- | 59.21 |
Assets (₹ Cr)
| Hiran Orgochem | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.20 | 3,983.17 | 53.02 | -- | 11.26 |
|
Current Assets
|
25.29 | 3,521.56 | 30.88 | -- | 47.65 |
|
Total Assets
|
25.49 | 7,504.73 | 83.90 | -- | 59.21 |
|
Total Debt*
|
65.46 | 2,010.07 | 26.03 | -- | 22.92 |
|
Net Current Assets
|
-61.87 | 1,748.59 | 6.46 | -- | 9.84 |
|
Contingent Liabilities
|
12.27 | 295.45 | 0.70 | -- | -- |
Cashflow (₹ Cr)
| Hiran Orgochem | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-16.08 | 354.96 | 10.55 | -- | -3.88 |
|
Cash Flow from Investing Activities
|
16.13 | -206.63 | -4.09 | -- | -4.44 |
|
Cash from Financing Activities
|
0.00 | -75.65 | -10.21 | -- | 8.61 |
|
Net Cash Inflow / Outflow
|
0.05 | 72.68 | 0.34 | -- | 0.29 |
Ratios
Profitability Ratios
| Hiran Orgochem | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-102.40 | 11.25 | 9.04 | -- | 25.03 |
|
ROE (%)
|
0.00 | 12.49 | 9.82 | -- | 31.99 |
|
ROA (%)
|
-54.90 | 5.84 | 3.33 | -- | 8.42 |
|
EBIT Margin (%)
|
-6,559.89 | 17.31 | 29.29 | -- | 7.44 |
|
Net Margin (%)
|
-2,127.23 | 9.07 | 6.75 | -- | 3.66 |
|
Cash Profit Margin (%)
|
-5,838.68 | 12.43 | 19.93 | -- | 4.31 |
Growth Ratios
| Hiran Orgochem | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-84.04 | -7.22 | -5.70 | -- | 46.82 |
|
EBIT Growth (%)
|
-401.51 | -27.08 | -2.08 | -- | 24.42 |
|
Net Profit Growth (%)
|
-284.66 | -51.03 | -40.70 | -- | 42.98 |
|
EPS Growth (%)
|
-284.66 | -42.48 | -40.70 | -- | 42.98 |
|
Book Value Growth (%)
|
-80.22 | 4.11 | 10.33 | -- | 37.67 |
Valuation Ratios
| Hiran Orgochem | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Price / Earnings
|
0.00 | 46.73 | 0.00 | -- | 0.00 |
|
Price / Book Value
|
-0.08 | 6.09 | 0.00 | -- | 0.00 |
|
Dividend Yield (%)
|
0.00 | 1.07 | -- | -- | -- |
|
EV/EBITDA
|
-2.53 | 27.84 | 4.00 | -- | 2.87 |
|
Market Cap (₹ Cr)
|
4.74 | 20,529.92 | 0.00 | -- | 0.00 |
Solvency Ratios
| Hiran Orgochem | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-1.05 | 0.55 | 0.55 | -- | 1.55 |
|
Short term debt to equity ratio
|
-1.04 | 0.09 | 0.27 | -- | 0.97 |
|
Current Ratio
|
0.29 | 1.99 | 1.26 | -- | 1.26 |
|
Quick Ratio
|
0.28 | 1.41 | 1.22 | -- | 0.89 |
|
Interest Coverage
|
-5,278.19 | 11.42 | 2.66 | -- | 4.78 |
Operating Efficiency Ratios
| Hiran Orgochem | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
86.60 | 16.54 | 42.87 | -- | 21.80 |
|
Asset Turnover
|
0.01 | 0.64 | 0.49 | -- | 2.30 |
|
Receivable days
|
3,341.48 | 49.71 | 143.12 | -- | 61.92 |
|
Inventory Days
|
824.75 | 81.88 | 10.03 | -- | 41.26 |
|
Payable days
|
0.00 | 136.23 | 216.06 | -- | 94.00 |
|
Cash Conversion Cycle
|
4,166.23 | -4.64 | -62.91 | -- | 9.17 |